New hope for ulcerative colitis: drug shows promise in early trial

This study tested a new drug called IBI112 in 150 people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. The goal was to see if IBI112 could help patients achieve remission (no symptoms) after 12 weeks of treatment. Participants were randomly assigned to receive either IBI112 or a placebo, and neither they nor their doctors knew which they received.